Page last updated: 2024-11-11

pradefovir mesylate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pradefovir: a HepDirect prodrug of adefovir; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9604653
CHEMBL ID3989658
MeSH IDM0482044

Synonyms (29)

Synonym
625095-61-6
pradefovir mesylate (usan)
D05588
remofovir mesylate
icn-2001-3
mb-6866
pradefovir mesylate
hepavir b
mb-06866 ,
mb-06866q
9-(2-(4-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl)methoxyethyl)adenine
pradefovir mesylate [usan]
9h-purin-6-amine, 9-(2-(((2r,4s)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl)-methoxy)ethyl)-, monomethanesulfonate;
unii-0d5204zsix
mb 06866q
0d5204zsix ,
pradefovir
pradefovir mesilate [who-dd]
pradefovir mesilate
DB05478
DTXSID00211558
mb6866
CHEMBL3989658
Q27095685
HY-112690A
CS-0062746
pradefovir mesylate (remofovir mesylate)
EX-A1921
9-[2-[[(2r,4s)-4-(3-chlorophenyl)-2-oxo-1,3,2lambda5-dioxaphosphinan-2-yl]methoxy]ethyl]purin-6-amine;methanesulfonic acid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" No subject experienced a serious adverse event or nephrotoxicity."( Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection.
Chen, H; Ding, Y; Jin, W; Li, C; Li, X; Liu, C; Liu, J; Niu, J; Wu, M; Zhang, D; Zhang, H; Zhu, X, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
" The half-life of PMEA in the pradefovir group was 11."( Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection.
Chen, H; Ding, Y; Jin, W; Li, C; Li, X; Liu, C; Liu, J; Niu, J; Wu, M; Zhang, D; Zhang, H; Zhu, X, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
" Oral absorption and bioavailability were 29."( Single-dose pharmacokinetics and metabolism of [14C]remofovir in rats and cynomolgus monkeys.
Lin, CC; Lourenco, D; Xu, C; Yeh, LT; Zhu, N, 2005
)
0.33
" The lead prodrug (14, MB06866, pradefovir), identified from a variety of in vitro and in vivo assays, exhibited good oral bioavailability (F = 42%, mesylate salt, rat) and rate of prodrug conversion to ADV-DP."( Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B.
Boyer, SH; Colby, TJ; Craigo, W; DaRe, J; Erion, MD; Fujitaki, JM; Gómez-Galeno, JE; Matelich, MC; Ollis, K; Reddy, KR; Sun, Z; Ugarkar, BG; van Poelje, PD, 2008
)
0.35

Dosage Studied

ExcerptRelevanceReference
" Dose-limiting nephrotoxicity necessitates suboptimal dosing at 10 mg/day."( Remofovir mesylate: a prodrug of PMEA with improved liver-targeting and safety in rats and monkeys.
Erion, MD; Hong, Z; Lin, CC; Vitarella, D; Yeh, LT, 2004
)
0.32
" dosing of [(14)C]remofovir, fecal excretion of radioactivity accounted for 37."( Single-dose pharmacokinetics and metabolism of [14C]remofovir in rats and cynomolgus monkeys.
Lin, CC; Lourenco, D; Xu, C; Yeh, LT; Zhu, N, 2005
)
0.33
"The pharmacokinetics of pradefovir and adefovir, 9-(2-phosphonylmethoxyethyl) adenine (PMEA), was evaluated in healthy male volunteers after oral dosing of pradefovir (10, 30, or 60 mg)."( Pharmacokinetics of pradefovir and PMEA in healthy volunteers after oral dosing of pradefovir.
Lin, CC; Peterson, J; Teng, A; Xu, C; Yeh, LT, 2005
)
0.33
" The enzyme induction potential of pradefovir was evaluated in rats following multiple oral dosing and in primary cultures of human hepatocytes."( Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer.
Benetton, S; Fang, C; Lin, CC; Xu, GF; Yeh, LT, 2006
)
0.33
"Adefovir dipivoxil, a marketed drug for the treatment of hepatitis B, is dosed at submaximally efficacious doses because of renal toxicity."( Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B.
Boyer, SH; Colby, TJ; Craigo, W; DaRe, J; Erion, MD; Fujitaki, JM; Gómez-Galeno, JE; Matelich, MC; Ollis, K; Reddy, KR; Sun, Z; Ugarkar, BG; van Poelje, PD, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (66.67)29.6817
2010's2 (16.67)24.3611
2020's2 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.63 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (33.33%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (58.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]